Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Athira Pharma shares update on its ACT-AD and LIFT-AD studies of Alzheimer’s candidate ATH-1017

By Brian Buntz | November 10, 2021

Athira PharmaAthira Pharma (NSDQ:ATHA) announced that its lead development candidate, ATH-1017, had balanced baseline characteristics to date in two ongoing late-stage Alzheimer’s studies.

Presenting the data at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, the company’s chief medical officer Dr. Hans Moebius said that the baseline characteristics are consistent between the ACT-AD and LIFT-AD studies.

Athira expects topline data from the ACT-AD to be available in the first half of 2022.

ACT-AD is a six-month double-blind Phase 2 trial while LIFT-AD is a six-month double-blind Phase 2/3 study.

ATH-1017 is a subcutaneously delivered small molecule drug that can cross the blood-brain barrier. The drug is designed to improve the activity of the hepatocyte growth factor (HGF) and its receptor, MET. The levels of both HGF and MET tend to be reduced in Alzheimer’s patients.

The company’s Aβ- and tau-agnostic strategy for treating Alzheimer’s is different from many other drug companies subscribing to the amyloid cascade hypothesis or tau hypothesis.

Prior Phase 1 research involving ATH-1017 found it to be well tolerated.

The company has also conducted preclinical research to test ATH-1017’s potential in Parkinson’s disease.

In October, the company announced that it had installed its former chief operating officer, Mark Litton, as CEO. The company’s former CEO, Leen Kawas, had resigned amidst allegations that she had manipulated images in at least four research papers published between 2011 and 2014.

Athira Pharma, initially known as M3 Biotechnology, first intended to commercialize Dihexa, a drug candidate discovered at Washington State University. Upon concluding that the drug did not have appropriate drug-like characteristics, the company investigated more than 50 compounds that activate the HGF/MET pathway. That research eventually led to the selection of ATH-1017, a prodrug to Dihexa. After subcutaneous administration, the body immediately converts ATH-1017 to an active metabolite in the plasma.

The company concluded that ATH-1017 has superior drug-like properties compared to Dihexa, including solubility and pharmacokinetics.

Athira won a patent for ATH-1017 in June.


Filed Under: clinical trials, Drug Discovery, Neurological Disease
Tagged With: ACT-AD, Alzheimer's disease, ATH-1017, Athira Pharma, Dihexa
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50